[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388150":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":52,"collaborators":54,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":11,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":88,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University Hospital, Lille","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IMMINeNT cohort","EXPERIMENTAL",null,[13,14],"Genetic: Biobanking with genetic analysis","Other: SF-12 questionnaire",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"GENETIC","Biobanking with genetic analysis","Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.",[9],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"SF-12 questionnaire","Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.",[9],[26],{"name":27,"affiliation":5,"role":28},"David Launay, MD,PhD","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","03 20 44 42 95","+33","david.launay@chru-lille.fr",[36],{"facility":37,"status":38,"city":39,"state":11,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Hop Claude Huriez Chu Lille","RECRUITING","Lille","59037","France","FR",{"type":44,"coordinates":45},"Point",[46,47],3.05512,50.63391,{"lat":47,"lon":46},[50],{"name":11,"role":31,"phone":51,"phoneExt":11,"email":11},"0320445962",{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[55,58,60],{"name":56,"class":57},"FHU IMMINeNT","UNKNOWN",{"name":59,"class":57},"FHU PRECISE: Projet Fédératif Hospitalo-Universitaire PREcision health in Complex Immune-mediated inflammatory diseaSEs",{"name":61,"class":57},"Fond de dotation de la Société Française de Dermatologie (SFD)","100388150","deployment-o-the-multidisciplinary-prospective-cohort-imminent-100388150",false,"NCT04334031","Deployment o the Multidisciplinary Prospective Cohort Imminent","IMMINeNT","Inclusion Criteria:\n\n* Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology)\n* Social insured\n* Have the capacity to understand the study requirements, provide written informed consent, and comply with the study data collection procedures.\n\nExclusion Criteria:\n\n* Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system.\n* Pregnant or breastfeeding woman\n* Persons deprived of liberty\n* Protected minors or adults\n* Persons who have refused or are incapable of giving informed consent\n* Persons in Emergency Situations","ALL","18 Years",{"count":72,"type":73},2200,"ESTIMATED","INTERVENTIONAL",[76],"NA","Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions.\n\nBeyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as \"targeted therapies\". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment.\n\nThese similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.",[79,80,81,82,83,84,85,86,87],"Chronic Inflammatory Disease","Angioedema","Severe Asthma","Lupus","Atopic Dermatitis","Psoriatic Arthritis","Multiple Sclerosis","Systemic Sclerosis","Behçet Disease",[89,90,91,92,93],"Immune Mediated Inflammatory Diseases (IMIDs)","biomarker","cohort study","quality of life","disease severity","2026-04-28",{"date":96,"type":97},"2026-05-05","ACTUAL",{"date":99,"type":97},"2020-07-20",{"date":101,"type":73},"2031-07-21",{"name":5,"class":6},1]